This week, the overall grades of 17 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, TESARO, Inc. (TSRO) drops from a C to a D rating. TESARO, Inc. develops and commercializes cancer therapeutics and supportive care products. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TSRO stock.

SAGE Therapeutics, Inc. (SAGE) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of SAGE stock.

AMAG Pharmaceuticals, Inc. (AMAG) earns a F this week, moving down from last week’s grade of D. AMAG Pharmaceuticals, Inc. utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The company also gets F’s in operating margin growth, earnings growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AMAG stock.

Insmed Incorporated (INSM) declines this week from a D to a F. Insmed Incorporated develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of INSM stock.

Momenta Pharmaceuticals, Inc. (MNTA) is having a tough week. The company’s rating falls from a D to a F. Momenta Pharmaceuticals, Inc. is a biotechnology company which specializes in sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company also gets F’s in earnings revisions and return on equity. For more information, get Portfolio Grader’s complete analysis of MNTA stock.

Slipping from a D to a F rating, Karyopharm Therapeutics, Inc. (KPTI) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of KPTI stock.

This week, Merrimack Pharmaceuticals, Inc.’s (MACK) rating worsens to a D from the company’s C rating a week ago. Merrimack Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of MACK stock.

Tokai Pharmaceuticals, Inc. (TKAI) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TKAI stock.

Chimerix, Inc. (CMRX) slips from a D to a F this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CMRX stock.

Dicerna Pharmaceuticals, Inc.’s (DRNA) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DRNA stock.

This is a rough week for Progenics Pharmaceuticals, Inc. (PGNX). The company’s rating falls to D from the previous week’s C. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets F’s in operating margin growth, earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Asterias Biotherapeutics Inc Class A (AST) declines this week from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of AST stock.

Stellar Biotechnologies, Inc. (SBOT) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of SBOT stock.

Kindred Biosciences, Inc.’s (KIN) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of KIN stock.

This week, Cancer Genetics, Inc. (CGIX) drops from a D to a F rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CGIX stock.

This week, Rosetta Genomics Ltd’s (ROSG) rating worsens to a F from the company’s D rating a week ago. Rosetta Genomics Ltd is a biomedical company that discovers and develops diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ROSG stock.

Slipping from a D to a F rating, Transition Therapeutics Inc. (TTHI) takes a hit this week. Transition Therapeutics Inc. is a biopharmaceutical company focused on developing novel therapeutics in order to address global medical needs in large disease indications, including Alzheimer’s disease and diabetes. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of TTHI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.